US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lipella Pharmaceuticals Inc

2.65

+0.07002.71%

Post-market: 2.720.0700+2.64%19:55 EDT

Volume:89.04K

Turnover:236.58K

Market Cap:6.75M

PE:-0.55

High:2.74

Open:2.54

Low:2.54

Close:2.58

Loading ...

Overview Company News Filings

Lipella Pharmaceuticals Inc - to Submit Phase 2B Ind Application and Breakthrough Therapy Request in H2 2025

THOMSON REUTERS

Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for Lp-310 in the Treatment of Oral Lichen Planus

THOMSON REUTERS

Lipella Pharmaceuticals Inc - Lp-310 Shows Strong Safety Profile, No Serious Adverse Events

THOMSON REUTERS

Top Midday Gainers

MT Newswires Live

Dow Edges Higher; US Weekly Jobless Claims Increase

Investor Sentiment Muted Amid Earnings Deluge, Stifling US Equity Futures Pre-Bell

MT Newswires Live

Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for Lp-310 in Oral Lichen Planus

THOMSON REUTERS

Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus

Spartan Capital Securities, Llc Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $875,500 Private Placement

THOMSON REUTERS

Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $875,500 Private Placement

Lipella Pharmaceuticals announces publication in CUREUS

Lipella Pharmaceuticals Announces Publication in Cureus on Non-Steroid Treatment of Oral Lichen Planus

THOMSON REUTERS

BUZZ-Lipella rises after completing dosing of patient group in drug trial

BRIEF-Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310

Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of Lp-310 for Oral Lichen Planus, Advancing to Next Dose Group

THOMSON REUTERS

Lipella Pharmaceuticals Inc - Trial Expected to Conclude by Mid-2025 With Top-Line Data by Year-End 2024

THOMSON REUTERS

Maxim Group Keeps Their Buy Rating on Lipella Pharmaceuticals, Inc. (LIPO)

Lipella Pharmaceuticals Third Quarter 2024 Earnings: US$1.29 loss per share (vs US$1.84 loss in 3Q 2023)

Simply Wall St.

Lipella Pharmaceuticals Faces Nasdaq Delisting Risk Amid Compliance Challenges

Lipella Pharmaceuticals announces 1-for-8 reverse stock split

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/LIPO/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LIPO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LIPO\",,,,,undefined,":{"symbol":"LIPO","market":"US","secType":"STK","nameCN":"Lipella Pharmaceuticals Inc","latestPrice":2.65,"timestamp":1745611200000,"preClose":2.58,"halted":0,"volume":89042,"hourTrading":{"tag":"盘后","latestPrice":2.72,"preClose":2.65,"latestTime":"19:55 EDT","volume":20388,"amount":55071.27,"timestamp":1745625347537},"delay":0,"floatShares":2326756,"shares":2548811,"eps":-4.789999,"marketStatus":"Closed","change":0.07,"latestTime":"04-25 16:00:00 EDT","open":2.54,"high":2.74,"low":2.54,"amount":236584.059748,"amplitude":0.077519,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.789999,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745827200000},"marketStatusCode":5,"adr":0,"listingDate":1671512400000,"exchange":"NASDAQ","adjPreClose":2.58,"preHourTrading":{"tag":"盘前","latestPrice":2.56,"preClose":2.58,"latestTime":"08:10 EDT","volume":2687,"amount":7312.678561,"timestamp":1745583007700},"postHourTrading":{"tag":"盘后","latestPrice":2.72,"preClose":2.65,"latestTime":"19:55 EDT","volume":20388,"amount":55071.27,"timestamp":1745625347537},"volumeRatio":0.154279},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LIPO\",,,,,undefined,":{"symbol":"LIPO","floatShares":2326756,"roa":"-101.59%","roe":"-198.12%","lyrEps":-4.785666,"volumeRatio":0.154279,"shares":2548811,"dividePrice":0,"high":2.74,"amplitude":0.077519,"preClose":2.58,"low":2.54,"week52Low":1.965,"pbRate":"3.52","psRate":"12.59","week52High":12,"institutionHeld":0,"latestPrice":2.65,"eps":-4.789999,"divideRate":0,"volume":89042,"delay":0,"ttmEps":-4.789999,"open":2.54,"prevYearClose":3.05,"prevWeekClose":2.4,"prevMonthClose":2.51,"prevQuarterClose":2.51,"fiveDayClose":2.4,"twentyDayClose":2.72,"sixtyDayClose":2.71},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LIPO\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2510809759","title":"Lipella Pharmaceuticals Inc - to Submit Phase 2B Ind Application and Breakthrough Therapy Request in H2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2510809759","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510809759?lang=en_us&edition=fundamental","pubTime":"2025-02-11 18:46","pubTimestamp":1739270812,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nFWN3P11GN:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIPO","BK4139"],"gpt_icon":0},{"id":"2510780929","title":"Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for Lp-310 in the Treatment of Oral Lichen Planus","url":"https://stock-news.laohu8.com/highlight/detail?id=2510780929","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510780929?lang=en_us&edition=fundamental","pubTime":"2025-02-11 18:46","pubTimestamp":1739270812,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nFWN3P11GN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LIPO"],"gpt_icon":0},{"id":"2510218809","title":"Lipella Pharmaceuticals Inc - Lp-310 Shows Strong Safety Profile, No Serious Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2510218809","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510218809?lang=en_us&edition=fundamental","pubTime":"2025-02-11 18:46","pubTimestamp":1739270812,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250211:nFWN3P11GN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIPO","BK4139"],"gpt_icon":0},{"id":"2509005322","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2509005322","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509005322?lang=en_us&edition=fundamental","pubTime":"2025-02-07 02:43","pubTimestamp":1738867391,"startTime":"0","endTime":"0","summary":"Lipella Pharmaceuticals  shares soared 79% after the company said Thursday it received a US Food and Drug Administration approval for an expanded access program for LP-310, an oral rinse formulation designed to treat oral lichen planus.Over 82.1 million shares traded intraday versus a daily average of roughly 127,000.TransCode Therapeutics  said Thursday that Cohort 3 of its Phase 1 clinical trial enrolled three patients and all have been dosed with TTX-MC138, its lead candidate. The dose administered to patients in the cohort was about double that of Cohort 2.Shares jumped nearly 33% as intraday trading volume climbed to more than 11.7 million from a daily average of over 1.44 million.Tapestry  reported Thursday higher fiscal Q2 non-GAAP earnings and net sales while raising its outlook for fiscal 2025.Shares rose roughly 13%, with intraday trading volume rising to nearly 10.6 million, compared with a daily average of more than 4.87 million.Price: 4.69, Change: +2.07, Percent Change: +","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0052756011.USD","RNAZ","BK4588","LU1267930227.SGD","TPR","LU0070302665.USD","LU0310800965.SGD","BK4139","BK4516","BK4585","LU0320765489.SGD","LU0128525689.USD","LU0208291251.USD","BK4202","BK4539","LIPO"],"gpt_icon":0},{"id":"2509277765","title":"Dow Edges Higher; US Weekly Jobless Claims Increase","url":"https://stock-news.laohu8.com/highlight/detail?id=2509277765","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509277765?lang=en_us&edition=fundamental","pubTime":"2025-02-06 23:06","pubTimestamp":1738854417,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"d692b68f53e736a66ee6c4966456b3a5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/25/02/43531523/dow-edges-higher-us-weekly-jobless-claims-increase","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SRTS","RETO","BK4139","TQQQ","QID","LIPO","QNTM","BK4023","NVIW.SI","NQmain","PSQ",".IXIC","SQQQ","USAW.SI","AVGR","BK4011","BK4585","MNQmain","USJW.SI","BK4007","BK4588","BK4082","TSYW.SI","APPS","QLD"],"gpt_icon":1},{"id":"2509052279","title":"Investor Sentiment Muted Amid Earnings Deluge, Stifling US Equity Futures Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2509052279","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509052279?lang=en_us&edition=fundamental","pubTime":"2025-02-06 22:05","pubTimestamp":1738850748,"startTime":"0","endTime":"0","summary":"US equity futures were flat ahead of Thursday's opening bell as traders digested a deluge of corporate earnings.The Dow Jones Industrial Average futures increased 0.1%, S&P 500 futures gained 0.1%, wh","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":[".IXIC","LIPO",".SPX","LLY",".DJI","RBLX","SWKS","MTRX","EQR","AMZN","PM"],"gpt_icon":1},{"id":"2509225720","title":"Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for Lp-310 in Oral Lichen Planus","url":"https://stock-news.laohu8.com/highlight/detail?id=2509225720","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509225720?lang=en_us&edition=fundamental","pubTime":"2025-02-06 19:00","pubTimestamp":1738839600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nTUA6BMPB1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LIPO"],"gpt_icon":0},{"id":"2509998226","title":"Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus","url":"https://stock-news.laohu8.com/highlight/detail?id=2509998226","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509998226?lang=en_us&edition=fundamental","pubTime":"2025-02-06 19:00","pubTimestamp":1738839600,"startTime":"0","endTime":"0","summary":"PITTSBURGH, Feb. 06, 2025  -- Lipella Pharmaceuticals Inc.  , a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced that the U.S. Food and Drug Administration  has granted approval for an Expanded Access Program  for LP-310, an oral rinse formulation designed to treat oral lichen planus .LP-310 is an innovative, localized therapy formulated to provide targeted relief for OLP patients while minimizing systemic exposure. Oral lichen planus is a chronic inflammatory condition affecting the mucous membranes inside the mouth, often causing burning pain, white patches, swollen tissue and open sores. The condition impacts approximately 6 million Americans and currently has no FDA-approved therapies.Forward-Looking StatementsThis press release includes certain \"forward-looking statements.\" All statements, other than statements of historical fact, included in this press release regarding, among other things,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lipella-pharmaceuticals-granted-fda-approval-110000849.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LIPO","BK4139","OLP","BK4160"],"gpt_icon":0},{"id":"2502180358","title":"Spartan Capital Securities, Llc Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $875,500 Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2502180358","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502180358?lang=en_us&edition=fundamental","pubTime":"2025-01-11 02:24","pubTimestamp":1736533478,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nTUAYS0Z0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIPO","BK4139"],"gpt_icon":0},{"id":"2502138658","title":"Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.’s $875,500 Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2502138658","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502138658?lang=en_us&edition=fundamental","pubTime":"2025-01-11 02:24","pubTimestamp":1736533440,"startTime":"0","endTime":"0","summary":"New York, NY, Jan. 10, 2025  -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the successful completion of two private placements for Lipella Pharmaceuticals Inc. . Spartan Capital Securities, LLC acted as the sole placement agent in these private offerings of Series B non-voting convertible preferred stock of Lipella Pharmaceuticals Inc., raising an aggregate total of $875,500 through the transactions.“We are proud to serve as the sole placement agent in these private placements for Lipella Pharmaceuticals,” said John Lowry, CEO of Spartan Capital Securities. “Lipella’s dedication to developing innovative therapies aimed at improving patient outcomes is inspiring. These successful transactions reflect both the strength of Lipella’s clinical pipeline and Spartan Capital’s commitment to facilitating impactful investment opportunities. We look forward to supporting Lipella’s future growth and success.”Spartan Capital Securities, LLC is a premi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spartan-capital-securities-llc-serves-182400686.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LIPO","BK4139","SPAQ.U"],"gpt_icon":0},{"id":"2488486779","title":"Lipella Pharmaceuticals announces publication in CUREUS","url":"https://stock-news.laohu8.com/highlight/detail?id=2488486779","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488486779?lang=en_us&edition=fundamental","pubTime":"2024-12-03 21:41","pubTimestamp":1733233267,"startTime":"0","endTime":"0","summary":"Lipella Pharmaceuticals (LIPO) announced the publication of a peer-reviewed paper in CUREUS. Titled “Rationale for the Use of Topical Calcineurin I...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lipella-pharmaceuticals-announces-publication-in-cureus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lipella-pharmaceuticals-announces-publication-in-cureus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LIPO","BK4139"],"gpt_icon":0},{"id":"2488917683","title":"Lipella Pharmaceuticals Announces Publication in Cureus on Non-Steroid Treatment of Oral Lichen Planus","url":"https://stock-news.laohu8.com/highlight/detail?id=2488917683","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488917683?lang=en_us&edition=fundamental","pubTime":"2024-12-03 21:30","pubTimestamp":1733232601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241203:nTUA6VNQTX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LIPO"],"gpt_icon":0},{"id":"2485632142","title":"BUZZ-Lipella rises after completing dosing of patient group in drug trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2485632142","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485632142?lang=en_us&edition=fundamental","pubTime":"2024-11-22 21:51","pubTimestamp":1732283472,"startTime":"0","endTime":"0","summary":"** Lipella Pharmaceuticals'    shares rise 7% to $2.59 premarket   ** LIPO says completed dosing of first group of patients in mid-stage study of LP-310, its key experimental drug to treat oral lichen planus   ** OLP is a chronic inflammatory disease that affects mucous membranes inside the mouth   ** Disease affects about 6-7 million Americans, and has no approved drug besides those used to alleviate symptoms, the co's website says    ** As of last close, stock had fallen 70% YTD ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LIPO","BK4139"],"gpt_icon":0},{"id":"2485446519","title":"BRIEF-Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310","url":"https://stock-news.laohu8.com/highlight/detail?id=2485446519","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485446519?lang=en_us&edition=fundamental","pubTime":"2024-11-21 18:45","pubTimestamp":1732185945,"startTime":"0","endTime":"0","summary":"BRIEF-Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of LP-310Nov 21 (Reuters) - Lipella Pharmaceuticals Inc LIPO.O:LIPELLA PHARMACEUTICALS ANNOUNCES COMPLETION OF FIRS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nTUA6Z2TL4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LIPO"],"gpt_icon":0},{"id":"2485463151","title":"Lipella Pharmaceuticals Announces Completion of First Cohort in Phase 2a Trial of Lp-310 for Oral Lichen Planus, Advancing to Next Dose Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2485463151","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485463151?lang=en_us&edition=fundamental","pubTime":"2024-11-21 18:30","pubTimestamp":1732185000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nTUA6Z2TL4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIPO","BK4139"],"gpt_icon":0},{"id":"2485046315","title":"Lipella Pharmaceuticals Inc - Trial Expected to Conclude by Mid-2025 With Top-Line Data by Year-End 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2485046315","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485046315?lang=en_us&edition=fundamental","pubTime":"2024-11-21 18:30","pubTimestamp":1732185000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241121:nTUA6Z2TL4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LIPO","BK4139"],"gpt_icon":0},{"id":"2484464641","title":"Maxim Group Keeps Their Buy Rating on Lipella Pharmaceuticals, Inc. (LIPO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2484464641","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484464641?lang=en_us&edition=fundamental","pubTime":"2024-11-20 23:45","pubTimestamp":1732117513,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Lipella Pharmaceuticals, Inc. (LIPO – Research Report). ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/maxim-group-keeps-their-buy-rating-on-lipella-pharmaceuticals-inc-lipo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/maxim-group-keeps-their-buy-rating-on-lipella-pharmaceuticals-inc-lipo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LIPO"],"gpt_icon":0},{"id":"2484635043","title":"Lipella Pharmaceuticals Third Quarter 2024 Earnings: US$1.29 loss per share (vs US$1.84 loss in 3Q 2023)","url":"https://stock-news.laohu8.com/highlight/detail?id=2484635043","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484635043?lang=en_us&edition=fundamental","pubTime":"2024-11-17 21:47","pubTimestamp":1731851264,"startTime":"0","endTime":"0","summary":"NasdaqCM:LIPO Earnings and Revenue History November 17th 2024. All figures shown in the chart above are for the trailing 12 month  period. Looking ahead, revenue is forecast to grow 97% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.The company's shares are down 26% from a week ago.It is worth noting though that we have found 6 warning signs for Lipella Pharmaceuticals (5 are potentially serious!) that you need to take into consideration.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lipella-pharmaceuticals-third-quarter-2024-134744326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LIPO"],"gpt_icon":0},{"id":"2483256186","title":"Lipella Pharmaceuticals Faces Nasdaq Delisting Risk Amid Compliance Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2483256186","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483256186?lang=en_us&edition=fundamental","pubTime":"2024-11-16 14:00","pubTimestamp":1731736821,"startTime":"0","endTime":"0","summary":"Lipella Pharmaceuticals, Inc. (LIPO) has disclosed a new risk, in the Share Price & Shareholder Rights category. Lipella Pharmaceuticals, Inc. is f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lipella-pharmaceuticals-faces-nasdaq-delisting-risk-amid-compliance-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lipella-pharmaceuticals-faces-nasdaq-delisting-risk-amid-compliance-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BKPKM429.USD","LU2095319765.USD","SQQQ","BK4112","IE00B3QW5Z07.USD","NQmain","LIPO","BK4139","IE00B64PRP62.GBP","QLD","QID","MNQmain","LU2210150020.SGD","IE00BGHQF748.EUR","LU2210149790.SGD","TQQQ","BK4588","BK4585","PSQ",".IXIC","NDAQ"],"gpt_icon":0},{"id":"2480501438","title":"Lipella Pharmaceuticals announces 1-for-8 reverse stock split","url":"https://stock-news.laohu8.com/highlight/detail?id=2480501438","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480501438?lang=en_us&edition=fundamental","pubTime":"2024-11-02 04:35","pubTimestamp":1730493335,"startTime":"0","endTime":"0","summary":"Lipella Pharmaceuticals (LIPO) announced that it intends to effect a 1-for-8 reverse stock split of its common stock effective as of 5:00 p.m. East...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/lipella-pharmaceuticals-announces-1-for-8-reverse-stock-split?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/lipella-pharmaceuticals-announces-1-for-8-reverse-stock-split?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LIPO","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":42,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LIPO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-08","symbol":"LIPO","defaultRemindTime":1731076200000,"type":"split","dateTimestamp":1731042000000,"forFactor":8,"toFactor":1,"ratio":8},{"market":"US","date":"2023-05-15","symbol":"LIPO","fiscalQuarterEnding":"2023/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1684123200000,"reportTimeType":"","actualEps":-0.19}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LIPO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LIPO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1712721600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LIPO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LIPO","date":"2025-04-24","current":-1.224544,"percent":0.546429,"low":-12.613414,"twenty":-4.051571,"median":-1.351639,"eighty":-0.861999,"high":-0.60491,"avg":-2.296088,"sd":1.875868,"marketCap":6142634},"quantilePoints":[{"date":"2022-12-16","current":-9.212167,"twenty":-9.212167,"median":-9.212167,"eighty":-9.212167,"marketCap":24121664},{"date":"2022-12-23","current":-8.796705,"twenty":-10.332031,"median":-9.541768,"eighty":-8.796705,"marketCap":23033793},{"date":"2022-12-30","current":-6.866084,"twenty":-9.963501,"median":-8.774659,"eighty":-7.296038,"marketCap":17978547},{"date":"2023-01-06","current":-6.778339,"twenty":-9.475847,"median":-7.710635,"eighty":-6.892408,"marketCap":17748790},{"date":"2023-01-13","current":-6.986735,"twenty":-8.96289,"median":-7.041576,"eighty":-6.892408,"marketCap":18294464},{"date":"2023-01-20","current":-5.506029,"twenty":-8.779068,"median":-7.019639,"eighty":-6.795888,"marketCap":14417301},{"date":"2023-01-27","current":-5.286666,"twenty":-8.471827,"median":-6.909957,"eighty":-5.628873,"marketCap":13842907},{"date":"2023-02-03","current":-5.945196,"twenty":-8.041874,"median":-6.822212,"eighty":-5.484093,"marketCap":15567239},{"date":"2023-02-10","current":-5.725393,"twenty":-7.77425,"median":-6.690594,"eighty":-5.492867,"marketCap":14991696},{"date":"2023-02-17","current":-5.176984,"twenty":-7.252165,"median":-6.47123,"eighty":-5.453382,"marketCap":13555710},{"date":"2023-02-24","current":-4.628794,"twenty":-7.037189,"median":-6.207993,"eighty":-5.374411,"marketCap":12120298},{"date":"2023-03-03","current":-3.970483,"twenty":-7.019639,"median":-5.879167,"eighty":-5.299828,"marketCap":10396540},{"date":"2023-03-10","current":-4.277592,"twenty":-7.013058,"median":-5.725393,"eighty":-4.705879,"marketCap":11200692},{"date":"2023-03-17","current":-5.176984,"twenty":-6.971379,"median":-5.495061,"eighty":-4.654898,"marketCap":13555710},{"date":"2023-03-24","current":-4.606638,"twenty":-6.909957,"median":-5.484093,"eighty":-4.654898,"marketCap":12062284},{"date":"2023-03-31","current":-4.277592,"twenty":-6.901182,"median":-5.467641,"eighty":-4.545216,"marketCap":11200692},{"date":"2023-04-06","current":-4.321465,"twenty":-6.866084,"median":-5.434736,"eighty":-4.321465,"marketCap":11315571},{"date":"2023-04-14","current":-3.935887,"twenty":-6.822212,"median":-5.374411,"eighty":-4.277592,"marketCap":10224222},{"date":"2023-04-21","current":-4.223339,"twenty":-6.822212,"median":-5.352475,"eighty":-4.223339,"marketCap":10970934},{"date":"2023-04-28","current":-4.798244,"twenty":-6.778339,"median":-5.176984,"eighty":-4.223339,"marketCap":12464360},{"date":"2023-05-04","current":-4.245451,"twenty":-6.637946,"median":-5.176984,"eighty":-4.218917,"marketCap":11028374},{"date":"2023-05-12","current":-4.11278,"twenty":-6.585299,"median":-4.826002,"eighty":-4.16573,"marketCap":10683737},{"date":"2023-05-19","current":-3.649357,"twenty":-6.493166,"median":-4.751857,"eighty":-4.122361,"marketCap":10683737},{"date":"2023-05-26","current":-3.433535,"twenty":-6.365146,"median":-4.672447,"eighty":-4.090947,"marketCap":10051903},{"date":"2023-06-02","current":-3.747458,"twenty":-6.259851,"median":-4.628794,"eighty":-4.046445,"marketCap":10970934},{"date":"2023-06-09","current":-3.727838,"twenty":-6.129022,"median":-4.551797,"eighty":-4.001194,"marketCap":10913495},{"date":"2023-06-16","current":-4.218343,"twenty":-5.984418,"median":-4.47502,"eighty":-3.990004,"marketCap":12349481},{"date":"2023-06-23","current":-3.957002,"twenty":-5.918785,"median":-4.356009,"eighty":-3.989199,"marketCap":11584388},{"date":"2023-06-30","current":-3.825939,"twenty":-5.813139,"median":-4.321465,"eighty":-3.98011,"marketCap":11200692},{"date":"2023-07-07","current":-4.218343,"twenty":-5.760491,"median":-4.296824,"eighty":-3.986737,"marketCap":12349481},{"date":"2023-07-14","current":-4.198723,"twenty":-5.747329,"median":-4.283633,"eighty":-3.991615,"marketCap":12292042},{"date":"2023-07-21","current":-4.002521,"twenty":-5.72978,"median":-4.277592,"eighty":-3.991615,"marketCap":11717647},{"date":"2023-07-28","current":-4.041761,"twenty":-5.637647,"median":-4.25662,"eighty":-3.991615,"marketCap":11832526},{"date":"2023-08-04","current":-3.806319,"twenty":-5.598162,"median":-4.245451,"eighty":-3.987295,"marketCap":11143253},{"date":"2023-08-11","current":-3.952489,"twenty":-5.523578,"median":-4.220841,"eighty":-3.9829,"marketCap":11571177},{"date":"2023-08-18","current":-3.197951,"twenty":-5.48848,"median":-4.218343,"eighty":-3.967787,"marketCap":11781979},{"date":"2023-08-25","current":-3.086945,"twenty":-5.484093,"median":-4.199975,"eighty":-3.935362,"marketCap":11373011},{"date":"2023-09-01","current":-3.118127,"twenty":-5.475319,"median":-4.198723,"eighty":-3.901869,"marketCap":11487890},{"date":"2023-09-08","current":-3.349959,"twenty":-5.466544,"median":-4.179116,"eighty":-3.818091,"marketCap":12342014},{"date":"2023-09-15","current":-3.289623,"twenty":-5.448995,"median":-4.170269,"eighty":-3.775494,"marketCap":12119723},{"date":"2023-09-21","current":-3.086945,"twenty":-5.435833,"median":-4.15149,"eighty":-3.747458,"marketCap":11373011},{"date":"2023-09-29","current":-2.400958,"twenty":-5.415655,"median":-4.124038,"eighty":-3.684673,"marketCap":8845675},{"date":"2023-10-06","current":-1.808513,"twenty":-5.38692,"median":-4.117949,"eighty":-3.617494,"marketCap":6662976},{"date":"2023-10-13","current":-1.460979,"twenty":-5.374411,"median":-4.106701,"eighty":-3.366674,"marketCap":5382578},{"date":"2023-10-20","current":-2.536312,"twenty":-5.370024,"median":-4.090812,"eighty":-3.295859,"marketCap":9344351},{"date":"2023-10-27","current":-1.811651,"twenty":-5.361249,"median":-4.090812,"eighty":-3.289623,"marketCap":6674536},{"date":"2023-11-03","current":-1.811651,"twenty":-5.352475,"median":-4.080243,"eighty":-3.225702,"marketCap":6674536},{"date":"2023-11-10","current":-1.937522,"twenty":-5.352475,"median":-4.061381,"eighty":-3.180489,"marketCap":7138271},{"date":"2023-11-17","current":-1.463141,"twenty":-5.31299,"median":-4.051571,"eighty":-3.149319,"marketCap":6282770},{"date":"2023-11-24","current":-1.446253,"twenty":-5.242793,"median":-4.046445,"eighty":-3.139965,"marketCap":6210221},{"date":"2023-12-01","current":-1.527352,"twenty":-5.176984,"median":-4.041761,"eighty":-3.108772,"marketCap":6558457},{"date":"2023-12-08","current":-1.392188,"twenty":-5.080464,"median":-4.029217,"eighty":-2.701857,"marketCap":5978063},{"date":"2023-12-15","current":-1.316496,"twenty":-4.900586,"median":-4.022141,"eighty":-2.447729,"marketCap":5653042},{"date":"2023-12-22","current":-1.208365,"twenty":-4.830389,"median":-4.008439,"eighty":-2.28715,"marketCap":5188726},{"date":"2023-12-29","current":-1.365155,"twenty":-4.804066,"median":-4.002521,"eighty":-1.937522,"marketCap":5861984},{"date":"2024-01-05","current":-1.473286,"twenty":-4.800573,"median":-3.990407,"eighty":-1.821103,"marketCap":6326300},{"date":"2024-01-12","current":-1.392188,"twenty":-4.770412,"median":-3.9829,"eighty":-1.808981,"marketCap":5978063},{"date":"2024-01-19","current":-1.31136,"twenty":-4.728868,"median":-3.970483,"eighty":-1.794113,"marketCap":5630987},{"date":"2024-01-26","current":-1.378671,"twenty":-4.685609,"median":-3.952979,"eighty":-1.753879,"marketCap":5920023},{"date":"2024-02-02","current":-1.438059,"twenty":-4.663673,"median":-3.933261,"eighty":-1.565197,"marketCap":6175035},{"date":"2024-02-09","current":-1.409862,"twenty":-4.641824,"median":-3.90442,"eighty":-1.542058,"marketCap":6053956},{"date":"2024-02-16","current":-1.409721,"twenty":-4.619932,"median":-3.845559,"eighty":-1.523065,"marketCap":6053350},{"date":"2024-02-23","current":-1.409862,"twenty":-4.597863,"median":-3.806319,"eighty":-1.484348,"marketCap":6053956},{"date":"2024-03-01","current":-1.407249,"twenty":-4.558378,"median":-3.783901,"eighty":-1.464948,"marketCap":6500035},{"date":"2024-03-08","current":-1.001041,"twenty":-4.52863,"median":-3.767078,"eighty":-1.446253,"marketCap":4623773},{"date":"2024-03-15","current":-1.125258,"twenty":-4.478872,"median":-3.737648,"eighty":-1.433801,"marketCap":5197526},{"date":"2024-03-22","current":-1.181039,"twenty":-4.47333,"median":-3.708218,"eighty":-1.423961,"marketCap":5455176},{"date":"2024-03-28","current":-1.097365,"twenty":-4.466568,"median":-3.649357,"eighty":-1.409862,"marketCap":5068689},{"date":"2024-04-05","current":-1.032742,"twenty":-4.356009,"median":-3.619338,"eighty":-1.409862,"marketCap":4770199},{"date":"2024-04-12","current":-1.12381,"twenty":-4.343402,"median":-3.433535,"eighty":-1.407249,"marketCap":5190837},{"date":"2024-04-19","current":-1.087153,"twenty":-4.321465,"median":-3.330705,"eighty":-1.393718,"marketCap":5021522},{"date":"2024-04-26","current":-1.079837,"twenty":-4.299529,"median":-3.292479,"eighty":-1.392188,"marketCap":4987730},{"date":"2024-05-03","current":-1.143088,"twenty":-4.296824,"median":-3.274033,"eighty":-1.378671,"marketCap":5279884},{"date":"2024-05-10","current":-1.234958,"twenty":-4.296824,"median":-3.235056,"eighty":-1.367566,"marketCap":5704227},{"date":"2024-05-17","current":-1.222599,"twenty":-4.289674,"median":-3.197016,"eighty":-1.351639,"marketCap":5798727},{"date":"2024-05-24","current":-1.049613,"twenty":-4.277592,"median":-3.180489,"eighty":-1.349994,"marketCap":4978261},{"date":"2024-05-31","current":-1.00271,"twenty":-4.277592,"median":-3.180489,"eighty":-1.311306,"marketCap":4755804},{"date":"2024-06-07","current":-1.039111,"twenty":-4.277592,"median":-3.149308,"eighty":-1.297195,"marketCap":4928452},{"date":"2024-06-14","current":-1.07439,"twenty":-4.271575,"median":-3.141522,"eighty":-1.250266,"marketCap":5095776},{"date":"2024-06-21","current":-1.032697,"twenty":-4.263571,"median":-3.133639,"eighty":-1.226278,"marketCap":4898029},{"date":"2024-06-28","current":-0.721124,"twenty":-4.259579,"median":-3.125844,"eighty":-1.221938,"marketCap":3420254},{"date":"2024-07-05","current":-0.708777,"twenty":-4.256427,"median":-3.094741,"eighty":-1.209762,"marketCap":3361691},{"date":"2024-07-12","current":-0.851494,"twenty":-4.249533,"median":-2.884267,"eighty":-1.191679,"marketCap":4038592},{"date":"2024-07-15","current":-0.737801,"twenty":-4.247492,"median":-2.732258,"eighty":-1.187013,"marketCap":3499353},{"date":"2024-08-02","current":-1.241241,"twenty":-4.245451,"median":-2.58025,"eighty":-1.188507,"marketCap":5887142},{"date":"2024-08-09","current":-1.095615,"twenty":-4.245451,"median":-2.515407,"eighty":-1.188507,"marketCap":5196448},{"date":"2024-08-16","current":-1.019849,"twenty":-4.226214,"median":-2.400958,"eighty":-1.17357,"marketCap":4224631},{"date":"2024-08-23","current":-0.821535,"twenty":-4.223339,"median":-2.29575,"eighty":-1.143088,"marketCap":3403136},{"date":"2024-08-30","current":-0.830535,"twenty":-4.218343,"median":-1.937522,"eighty":-1.134096,"marketCap":3440417},{"date":"2024-09-06","current":-0.792384,"twenty":-4.218343,"median":-1.827405,"eighty":-1.121965,"marketCap":3282377},{"date":"2024-09-13","current":-0.738971,"twenty":-4.218343,"median":-1.811651,"eighty":-1.109163,"marketCap":3061121},{"date":"2024-09-20","current":-0.831514,"twenty":-4.218343,"median":-1.808513,"eighty":-1.097365,"marketCap":3444470},{"date":"2024-09-27","current":-0.993512,"twenty":-4.20465,"median":-1.794411,"eighty":-1.092727,"marketCap":4115534},{"date":"2024-10-04","current":-0.771253,"twenty":-4.199224,"median":-1.780144,"eighty":-1.087001,"marketCap":3194847},{"date":"2024-10-11","current":-0.786319,"twenty":-4.198723,"median":-1.74076,"eighty":-1.078748,"marketCap":3257253},{"date":"2024-10-18","current":-1.056023,"twenty":-4.198723,"median":-1.581417,"eighty":-1.066515,"marketCap":4374480},{"date":"2024-10-25","current":-0.995085,"twenty":-4.198723,"median":-1.552404,"eighty":-1.063983,"marketCap":4122051},{"date":"2024-10-31","current":-0.953293,"twenty":-4.186959,"median":-1.545599,"eighty":-1.057071,"marketCap":3948928},{"date":"2024-11-08","current":-0.730787,"twenty":-4.179108,"median":-1.540868,"eighty":-1.050144,"marketCap":3027220},{"date":"2024-11-15","current":-0.735457,"twenty":-4.175218,"median":-1.523778,"eighty":-1.043965,"marketCap":3046564},{"date":"2024-11-22","current":-0.686217,"twenty":-4.169798,"median":-1.500319,"eighty":-1.040265,"marketCap":2925668},{"date":"2024-11-29","current":-0.881848,"twenty":-4.163548,"median":-1.473306,"eighty":-1.032715,"marketCap":3759738},{"date":"2024-12-06","current":-0.876177,"twenty":-4.152592,"median":-1.464996,"eighty":-1.024615,"marketCap":3735559},{"date":"2024-12-13","current":-0.731565,"twenty":-4.139606,"median":-1.460979,"eighty":-1.004487,"marketCap":3119011},{"date":"2024-12-20","current":-0.72873,"twenty":-4.127646,"median":-1.446253,"eighty":-0.99776,"marketCap":3106921},{"date":"2024-12-27","current":-0.941394,"twenty":-4.124038,"median":-1.442156,"eighty":-0.992392,"marketCap":4013611},{"date":"2025-01-03","current":-0.901697,"twenty":-4.124038,"median":-1.432737,"eighty":-0.97594,"marketCap":3844362},{"date":"2025-01-10","current":-0.898861,"twenty":-4.121001,"median":-1.423961,"eighty":-0.960116,"marketCap":3832273},{"date":"2025-01-17","current":-0.827973,"twenty":-4.116572,"median":-1.42078,"eighty":-0.950913,"marketCap":3530043},{"date":"2025-01-24","current":-0.83648,"twenty":-4.11393,"median":-1.409862,"eighty":-0.928165,"marketCap":3566311},{"date":"2025-01-31","current":-0.757085,"twenty":-4.105485,"median":-1.409862,"eighty":-0.901697,"marketCap":3227813},{"date":"2025-02-07","current":-1.318519,"twenty":-4.094929,"median":-1.409862,"eighty":-0.897954,"marketCap":5621473},{"date":"2025-02-14","current":-1.139881,"twenty":-4.09094,"median":-1.408485,"eighty":-0.896593,"marketCap":4859854},{"date":"2025-02-21","current":-0.969749,"twenty":-4.090812,"median":-1.403855,"eighty":-0.8975,"marketCap":4134502},{"date":"2025-02-28","current":-0.833644,"twenty":-4.090812,"median":-1.395763,"eighty":-0.89411,"marketCap":3554221},{"date":"2025-03-07","current":-0.723059,"twenty":-4.090755,"median":-1.392188,"eighty":-0.885409,"marketCap":3082743},{"date":"2025-03-14","current":-0.62098,"twenty":-4.082329,"median":-1.392188,"eighty":-0.878445,"marketCap":2647532},{"date":"2025-03-21","current":-0.737236,"twenty":-4.069314,"median":-1.37955,"eighty":-0.864835,"marketCap":3143189},{"date":"2025-03-28","current":-0.771262,"twenty":-4.065687,"median":-1.378671,"eighty":-0.861371,"marketCap":3288259},{"date":"2025-04-04","current":-1.270273,"twenty":-4.061381,"median":-1.373118,"eighty":-0.857462,"marketCap":6372027},{"date":"2025-04-11","current":-1.219463,"twenty":-4.057457,"median":-1.365155,"eighty":-0.859879,"marketCap":6117146},{"date":"2025-04-17","current":-1.224544,"twenty":-4.051571,"median":-1.351639,"eighty":-0.861161,"marketCap":6142634},{"date":"2025-04-24","current":-1.224544,"twenty":-4.051571,"median":-1.351639,"eighty":-0.861999,"marketCap":6142634}],"updateTime":1745635807677}}}